Search

Displaying results 2281 - 2290 of 10000 in total
  1. Drug

    Pramocaine

    go.drugbank.com/drugs/DB09345
    Approved

    Pramocaine is available by itself and in combination with other medications in various topical preparations. … It is used for many dermatological and anorectal/anogenital conditions including minor cuts/burns, insect bites, hives/rashes due to poison ivy exposure, hemorrhoids and other anorectal/anogenital disorders

    Mixtures: DG Health Antibiotic, DG Health AntibioticProducts: Ear Itch MD, First On Topical Analgesic
  2. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.

    Synonyms: Lu-177-PSMA-617, lutetium Lu 177-PSMA-617Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    [T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. … [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.

    Mixtures: TRIANSERIL 50 MG/25 MG KAPSUL, 20 ADET, Nu-triazide Tab 50 Mg/25 mgProducts: Dyrenium 100
  4. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

    Mixtures: COUGH - EN, COUGH - EN PLUS
  5. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    in 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  6. Target

    20-ketosteroid reductase (20-hydroxysteroid dehydrogenase)

    go.drugbank.com/bio_entities/BE0009795
    EnzymeHumans and other mammals

    Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstanediols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:10998348, PubMed:24434280). … Catalyzes the reduction of progesterone to less potent progestogen (20S)-hydroxypregn-4-en-3-one likely regulating ligand availability for progesterone receptors (PubMed:10998348, PubMed:11013348, PubMed

    Synonyms: 20-alpha-HSDFunction: 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity
  7. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    It has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.

  8. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.

    Mixtures: GENVOYA FILM COATED TABLET 150 MG/150 MG/200 MG/10 MG, STRIBILD FILM COATED TABLET 150 MG/150 MG/200 MG/245 MGCategories: Antivirals used in combination for the treatment of HIV infections
  9. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle.

  10. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia